Effect of Malignancy on Morbidity and Mortality in Left-sided Emergency Colorectal Resections

April 27, 2025 updated by: Yasir Musa Kesgin, MD, Kanuni Sultan Suleyman Training and Research Hospital
Patients who underwent emergency left sided colorectal resection in a single center between January 2023 and May 2024 were included. Demographics, Charlson comorbidity index, perforation, duration of surgery, primary anastomosis or end colostomy preference and benign or malign etiologies were examined. Morbidity was defined as Clavien Dindo grade III or higher complication. Risk factors for both morbidity and mortality were first evaluated with univariate analyzes. Then multivariable logistic regression tests were performed for both morbidity and mortality.

Study Overview

Detailed Description

Patients in a single center between January 2023 and May 2024 were included in this retrospective observational study. Included patients who were 18 years old or older and underwent emergency left-sided colorectal resection due to isolated colorectal pathology. Patients with diseases originated from a colonic segment proximal to left colon, surgeries performed for combined organ pathologies for various benign and malignant causes and those undergoing reoperation caused by complication of elective abdominal surgery were excluded Data of patients obtained via the hospital software system. Demographic data, Charlson comorbidity index (CCI) score and baseline characteristics, operative and postoperative results, primary anastomosis or end colostomy preference, length of hospital stay, presence of perforation and and benign or malign etiologies were investigated. Morbidity was defined as Clavien Dindo grade III or higher complication.

Risk factors for both morbidity and mortality were first evaluated using univariate analyzes. In univariate analysis for morbidity, patients divided two subgroups as patient with morbidity and the others without morbidity. After that these two subgroups compared in terms of all variables. For univariate mortality analysis also, patients divided again according to dying in first 90 days postoperatively or not. After that these mortality and alive subgroups analysed in terms of all variables. Pearson Chi Square, Student's t-test and Mann Whitney U tests were used when appropriate. Decision for normal distribution was given according to Kolmogorov- Smirnov test. Values for normally distributed variables expressed as mean±standard deviation (SD). Categorical variables are expressed as number and percentage. The variables that not showed a normal distribution expressed as median and 25-75 interquartile range values. The effects of risk factors on morbidity and mortality were expressed as the odds ratio with their 95% confidence intervals (CI). Statistical significance level was set at 0.05. The data were compiled and analyzed using the software SPSS for Windows, version 29.0 (SPSS, Chicago, IL)

Study Type

Observational

Enrollment (Actual)

76

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Istanbul, Turkey, 34303
        • University of Health Sciences, Kanuni Sultan Suleyman Training and Research Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients who were 18 years old or older and underwent emergency left-sided colorectal resection due to isolated colorectal pathology

Description

Inclusion Criteria:

  • Patients who were 18 years old or older and underwent emergency left-sided colorectal resection due to isolated colorectal pathology

Exclusion Criteria:

  • Patients with diseases originated from a colonic segment proximal to left colon, surgeries performed for combined organ pathologies for various benign and malignant causes and those undergoing reoperation caused by complication of elective abdominal surgery

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Emergency Left-Sided Colorectal Resections
Patients in a single center underwent emergency left-sided colorectal resection due to benign or malign colorectal pathology

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Morbidity
Time Frame: Postoperative 30 days
Morbidity was defined as Clavien Dindo grade III or higher postoperative complication.
Postoperative 30 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2024

Primary Completion (Actual)

October 1, 2024

Study Completion (Actual)

October 1, 2024

Study Registration Dates

First Submitted

January 24, 2025

First Submitted That Met QC Criteria

April 27, 2025

First Posted (Actual)

May 6, 2025

Study Record Updates

Last Update Posted (Actual)

May 6, 2025

Last Update Submitted That Met QC Criteria

April 27, 2025

Last Verified

January 1, 2025

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe